**Supplementary Table 1: Baseline demographics and clinical characteristics.**

|  |  |
| --- | --- |
| **Variables** | **Patients, *n* (%) or mean ±** **SD** |
| Gender  Male, *n* (%)  Female, *n* (%)  Age (years), mean ± SD  Age of onset (years), mean ± SD  Disease duration, mean ± SD  PASI baseline scores, mean ± SD  BSA (%), mean ± SD  BMI (kg/m2)  Comorbidities, *n* (%)  Hypertension  Dyslipidemia,  Diabetes  Psoriasis with scalp involvement  IGA mod 2011 score, *n* (%)  2  3  4  Smoke  Drink  Previous biological therapy, *n* (%)  Adalimumab  Secukinumab  Ustekinumab  DLQI, mean ± SD | |  | | --- | | 45 (72.6) | | 17 (27.4) | | 38.1 ± 15.3 | | 27.9 ± 13.9 | | 10.5 ± 10.2  15.8 ± 9.5  28.0 ± 18.1 | | 23.6 ± 3.4 |  |  | | --- | | 13 (21.0) | | 11 (17.7) | | 6 (9.7) | | 13 (21.0) | |  | | 2 (3.2) | | 50 (80.6) | | 10 (16.1) |   22 (35.5)  30 (48.4)  2 (3.2)  3 (4.8)  1 (1.6)  18.7 ± 7.9 |

BMI: Body mass index; BSA: Body surface area; DLQI: Dermatology life quality index; IGA mod 2011: Investigator's global assessment, 2011, modified (version scores range from 0 [clear skin] to 4 [severe disease]); PASI: Psoriasis area and severity index; SD: Standard deviation.